Core Viewpoint - Le Xin Medical (300562) shows a slight increase in stock price and mixed capital flow, indicating potential investor interest and varying market sentiment [1][2]. Group 1: Stock Performance - As of February 9, 2026, Le Xin Medical's stock closed at 14.81 yuan, up by 1.3% with a turnover rate of 3.71% and a trading volume of 60,100 hands, resulting in a transaction amount of 88.6174 million yuan [1]. - On the same day, the net outflow of main funds was 137,100 yuan, accounting for 0.15% of the total transaction amount, while retail investors experienced a net outflow of 711,830 yuan, representing 8.03% of the total [1]. Group 2: Financial Performance - In the third quarter of 2025, Le Xin Medical reported a total revenue of 757 million yuan for the first three quarters, reflecting a year-on-year increase of 0.1% [2]. - The net profit attributable to shareholders reached 65.6814 million yuan, marking a significant year-on-year increase of 29.99%, while the net profit after deducting non-recurring items was 59.6175 million yuan, up by 19.35% [2]. - For the third quarter alone, the company recorded a revenue of 236 million yuan, which is a decline of 8.53% year-on-year, but the net profit attributable to shareholders increased by 49.2% to 23.391 million yuan [2]. Group 3: Business Overview - Le Xin Medical's main business includes home medical devices, remote health management (RPM), and AI digital chronic disease management [2].

Core Viewpoint - LeXin Medical (300562) shows a slight increase in stock price and mixed capital flow data, indicating potential investor interest and varying market sentiment [1][2]. Financial Performance - For the first three quarters of 2025, LeXin Medical reported a main revenue of 757 million yuan, a year-on-year increase of 0.1% [2]. - The net profit attributable to shareholders reached 65.68 million yuan, reflecting a significant year-on-year increase of 29.99% [2]. - The net profit after deducting non-recurring items was 59.62 million yuan, up by 19.35% year-on-year [2]. - In Q3 2025, the company experienced a decline in quarterly main revenue to 236 million yuan, down 8.53% year-on-year [2]. - The quarterly net profit attributable to shareholders was 23.39 million yuan, showing a substantial increase of 49.2% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was 21.55 million yuan, up by 22.64% year-on-year [2]. - The company's debt ratio stands at 30.1%, with investment income of 4.33 million yuan and financial expenses of 2.01 million yuan [2]. - The gross profit margin is reported at 35.59% [2]. Business Overview - LeXin Medical's main business segments include home medical devices, remote health management (RPM), and AI digital chronic disease management [2]. Capital Flow Analysis - On February 5, 2026, the stock closed at 14.7 yuan, with a turnover rate of 2.74% and a trading volume of 44,400 hands, amounting to a total transaction value of 65.25 million yuan [1]. - The capital flow data for February 5 indicates a net inflow of 1.54 million yuan from main funds, accounting for 2.37% of the total transaction value [1]. - Retail investors experienced a net outflow of 2.66 million yuan, representing 4.08% of the total transaction value [1].

Market Overview - The A-share market experienced a significant decline on February 2, with the Shanghai Composite Index falling by 2.48% to close at 4015.75 points, the Shenzhen Component Index dropping by 2.69% to 13824.35 points, and the ChiNext Index decreasing by 2.46% to 3264.11 points. The Sci-Tech Innovation Index saw a sharper decline of 3.95%, closing at 1760.23 points [1][2]. Commodity Market - The domestic commodity futures market closed with widespread declines, with over ten varieties, including silver, platinum, palladium, and copper, hitting the limit down. Notably, silver and gold fell over 15%, while zinc dropped over 6%. Other commodities like low-sulfur fuel oil and pure benzene also saw declines of over 5% [2]. Sector Performance - The electric grid equipment sector showed resilience, with stocks such as Tongguang Cable and Senyuan Electric hitting the daily limit up. The sector's performance contrasts sharply with the overall market trend [3][4]. - The liquor sector continued its upward momentum, with stocks like Huangtai Liquor and Jinhui Liquor achieving multiple consecutive gains [5]. Trading Volume and Market Sentiment - The total trading volume in the Shanghai and Shenzhen markets reached 2.58 trillion yuan, a decrease of 250.8 billion yuan compared to the previous trading day. Over 4600 stocks declined, with 123 stocks hitting the daily limit down [5][8]. Capital Flow - Main capital flows showed net inflows into sectors such as electric grid equipment, banking, and food and beverage, while there were net outflows from semiconductor, communication, and non-ferrous metal sectors. Specific stocks like Zhongchao Holdings and Shenghong Technology saw significant net inflows [8]. Institutional Insights - Financial institutions expressed concerns about short-term market volatility, advising investors to manage positions carefully and consider buying on dips. Market confidence is still in a recovery phase following increased trading volumes in January [8].

| 申请主体 | 产品 | 申请事项 | 注册证编号 | 注册 | 型号、规格 | 主要变更内容 | 结构组成 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | | | 分类 | | | | | 广东乐心医 | 电子血 | 第二类医疗器 | 粤械注准 | | | 根据 GB9706.1 系列新标准， | 由主机、袖带 | | 疗电子股份 | | 械注册证变更 | | II 类 | CS-WBP1-C | | 以及充电线 | | 有限公司 | 压计 | 注册 | 20242070801 | | | 变更产品技术 | （选配）组成。 | | | | | | | | 要求。 | | 乐心医疗 2026 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2026-007 广东乐心医疗电子股份有限公司 关于完成医疗器械注册证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）近日收到广东省药品 监督管理局的通知，获悉公司申请的医疗器 ...

证券日报网讯 1月27日，乐心医疗发布公告称，公司预计2025年度归属于上市公司股东的净利润为8， 100万元～8，500万元，比上年同期增长32.00%～38.52%。 （文章来源：证券日报） ...

公司始终坚持战略变革延续，聚焦数字慢病管理领域，推动公司中长期战略规划与年度经营计划实施落 地。公司 2025 年度预计归属于上市公司股东的净利润较上年同期增长32.00%至 38.52%。报告期内，公 司持续优化现有业务、产品结构，积极提升高盈利客户占比，带动整体综合毛利率实现稳步提升。通过 内部运营的精细化管理，全面持续推进降本增效、优化资源配置，推动经营效率持续性改善。同时通过 优化应收账款管理机制、加强存货管理提高资产运营效率，最终实现利润的稳步增长。报告期内公司应 收账款周转率和存货周转率等运营能力指标得到有效提升，公司整体盈利水平显著提升。报告期内，非 经常性损益对公司净利润的影响金额预计为人民币630 万元。 格隆汇1月27日丨乐心医疗(300562.SZ)公布，预计2025年归属于上市公司股东的净利润8,100万元～ 8,500万元，比上年同期增长32.00%～38.52%，扣除非经常性损益后的净利润7,500万元～7,900万元，比 上年同期增长33.98%～41.13%。 ...

乐心医疗 2026 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2026-006 广东乐心医疗电子股份有限公司 单位：万元 | 项 目 | | 本会计年度 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | | | 8,100 | ～ | 8,500 | 6,136.42 | | | 比上年同期增长 | | 32.00% | ～ | 38.52% | | | 扣除非经常性损益 后的净利润 | | | 7,500 | ～ | 7,900 | 5,597.75 | | | 比上年同期增长 | | 33.98% | ～ | 41.13% | | 二、与会计师事务所沟通情况 本次业绩预告相关的财务数据未经会计师事务所审计，公司已就本次业绩预告相关事项 与会计师事务所进行了预沟通，双方在本次业绩预告方面不存在重大分歧，具体数据以最终 审计结果为准。 三、业绩变动原因说明 公司始终坚持战略变革延续，聚焦数字慢病管理领域，推动公司中长期战略规划与年度 经营计划实施落地。公司 2025 年度预计归属于上市 ...

| 申请主体 | 产品 | 申请事项 | 注册证编号 | 注册 | 主要变更内容 | 结构组成 | | --- | --- | --- | --- | --- | --- | --- | | | 名称 | | | 分类 | | | | 广东乐心医 疗电子股份 | 电子血 压计 | 第二类医 疗器械注 册证变更 | 粤械注准 | 类 II | 型号、规格变更；结构 及组成变更；产品技术 | 由主机、袖带以 及充电线（选配） | | 有限公司 | | | 20212070887 | | 要求变更。 | 组成。 | | | | 注册 | | | | | 本次医疗器械注册证变更内容为：（1）型号、规格由"LS818-NB、LS818-F、 LS818-B"变更为"LS818-F、LS818-B"；（2）结构及组成由"由主机、袖带 组成。"变更为"由主机、袖带以及充电线（选配）组成。"；（3）产品技术 要求变更。该产品示波法测量数据，适用于测量成人舒张压、收缩压、脉率，所 测数据通过液晶显示屏显示，测量数据可供诊断参考。 公司定位于"医疗级远程健康监测设备及服务提供商"，始终高度重视医疗 器械标准符合性，推动全系列产品 ...

Core Insights - The smart device industry is experiencing significant growth driven by increasing consumer demand and advancements in technology, with the market size in China projected to grow from 5,133 billion yuan in 2018 to 17,157 billion yuan by 2024, representing a compound annual growth rate (CAGR) of 22.28% [1][14][15] - The industry is categorized into three main segments: smart home, smart wearables, and smart mobility, each with distinct applications and market dynamics [3][16][17] Industry Overview - Smart devices integrate hardware, software, and internet technologies, enabling them to perform tasks such as data collection and self-optimization [1][14] - The market is expected to reach 20,979 billion yuan by 2025, indicating continued growth and innovation in the sector [1][14] Industry Development Stages - The smart device industry in China has evolved through three phases: the initial stage (1990s to early 2000s), the development stage (2000 to 2015), and the explosive growth stage (2015 to present), with significant technological advancements and market expansion occurring in the latter two phases [6][8] Industry Policies - The Chinese government has implemented various policies to support the smart device industry, including initiatives to promote digital transformation and the development of smart products across multiple sectors [8][9] Industry Value Chain - The smart device industry value chain consists of upstream raw materials, hardware, and software systems; midstream manufacturing; and downstream applications in sectors such as healthcare, education, and transportation [10][11] Market Segmentation - The smart home market is characterized by diverse competition among traditional appliance manufacturers and tech companies, with a focus on integrated solutions and consumer experience [15] - The smart wearable segment includes products like smart glasses and smartwatches, with significant growth potential driven by consumer acceptance and technological advancements [16][17] - The smart mobility sector, particularly smart cars, is rapidly expanding, with the market size projected to grow from 777 billion yuan in 2020 to 2,152 billion yuan by 2024, reflecting a CAGR of 29% [17][18] Competitive Landscape - The smart device industry is marked by an ecosystem of competition, with leading companies leveraging core technologies and brand advantages to create comprehensive solutions across various applications [18][19] Future Trends - The industry is expected to see innovations in human-computer interaction, moving towards more natural and multi-modal interfaces [21] - There will be a shift from single-product intelligence to integrated scene intelligence, enhancing cross-device collaboration and user experience [22] - Smart devices will increasingly focus on personalized health management, evolving into digital health assistants capable of providing tailored recommendations [24]

公告显示，该产品由主机和配件组成，基于电化学原理，与配套血糖试纸共同使用，用于家庭患者定量 检测指尖新鲜毛细血管全血和医院专业人士定量检测静脉全血中的葡萄糖浓度。产品仅供成人体外监测 使用。供医疗机构中专业人员专业检测以及熟练掌握该项操作的患有糖尿病的非专业人员或其家属操 作。血糖仪只用于监测糖尿病人血糖控制的效果，而不能用于糖尿病的诊断和筛查，也不能作为治疗药 物调整的依据。其中型号为"GBZ41-B"的血糖仪具备蓝牙功能，可将测量结果上传至指定APP，方便用 户及时查看个人及家人的健康情况。 （文章来源：证券日报） 本报讯 1月19日晚间，广东乐心医疗电子股份有限公司（以下简称"乐心医疗"）公告称，公司近日收到 广东省药品监督管理局的通知，公司申报的血糖仪医疗器械注册事宜已通过审批。 乐心医疗方面称，公司定位于"医疗级远程健康监测设备及服务提供商"，始终高度重视医疗器械标准符 合性，推动全系列产品向医疗级方向发展。上述血糖仪医疗器械注册证的取得，系公司募投项目"智能 血糖监测产品产业化建设项目"建设进程的重要里程碑，有助于公司增强产品竞争力，进一步拓展血糖 业务，将对公司战略落地起到积极作用。 ...